3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
16
Carcinoma, Renal Cell
13
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Clear-cell metastatic renal cell carcinoma
6
Myelodysplastic Syndromes
5
Lung Neoplasms
5
Prostatic Neoplasms
4
Leukemia, Myeloid, Acute
4
Brain Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Ovarian Neoplasms
3
Histiocytoma, Malignant Fibrous
3
Carcinoma, Transitional Cell
3
Carcinoma, Basal Cell
3
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Penile Neoplasms
2
Nasopharyngeal Carcinoma
2
Meningioma
2
Lymphoma
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Glioblastoma
2
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cisplatin
4
Carboplatin
4
Biopsy
4
trastuzumab deruxtecan
3
Trastuzumab
3
Platinum
3
Goserelin
3
Docetaxel
3
sacituzumab govitecan
2
pertuzumab
2
entrectinib
2
darolutamide
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
spartalizumab
1
selinexor
1
pyrotinib
1
luprolide acetate gel depot
1
lenvatinib
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
CTLA-4 Antigen
×
1 year
×
Clear all
No trials found.